Equities Analysts Set Expectations for Immunome Q1 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at Wedbush boosted their Q1 2025 earnings estimates for Immunome in a research note issued on Wednesday, March 19th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.51) for the quarter, up from their prior estimate of ($0.72). Wedbush has a “Outperform” rating and a $33.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.80) EPS and FY2027 earnings at ($1.35) EPS.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million.

IMNM has been the subject of several other research reports. Stephens reissued an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Lifesci Capital began coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Guggenheim decreased their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome presently has an average rating of “Buy” and a consensus target price of $25.50.

Immunome Stock Down 14.7 %

IMNM stock opened at $6.95 on Monday. The company has a market cap of $604.31 million, a price-to-earnings ratio of -0.86 and a beta of 1.93. Immunome has a twelve month low of $6.94 and a twelve month high of $26.70. The business has a 50 day moving average price of $9.67 and a two-hundred day moving average price of $11.44.

Insider Activity at Immunome

In related news, CTO Philip Tsai acquired 12,300 shares of the firm’s stock in a transaction on Monday, March 24th. The shares were purchased at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the acquisition, the chief technology officer now directly owns 33,300 shares in the company, valued at approximately $280,386. This trade represents a 58.57 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime acquired 7,000 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was bought at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the transaction, the director now directly owns 23,615 shares of the company’s stock, valued at approximately $193,879.15. This trade represents a 42.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 169,300 shares of company stock worth $1,323,536. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Institutional investors have recently made changes to their positions in the company. Enavate Sciences GP LLC bought a new position in shares of Immunome during the fourth quarter worth approximately $36,939,000. JPMorgan Chase & Co. grew its holdings in Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after buying an additional 624,045 shares in the last quarter. Janus Henderson Group PLC increased its position in Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after buying an additional 324,614 shares during the period. Granahan Investment Management LLC acquired a new stake in shares of Immunome during the fourth quarter worth $3,337,000. Finally, Renaissance Technologies LLC boosted its position in shares of Immunome by 2,696.5% in the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock valued at $3,356,000 after acquiring an additional 304,700 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.